{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:39:11Z","timestamp":1761514751678,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Ministerio de Econom\u00eda, Industria y Competitividad, Gobierno de Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.berh.2021.101671","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T08:33:50Z","timestamp":1617784430000},"page":"101671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antifibrotics in systemic sclerosis"],"prefix":"10.1016","volume":"35","author":[{"given":"Maria","family":"Martin-Lopez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia E.","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.berh.2021.101671_bib1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2021.101671_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"25","key":"10.1016\/j.berh.2021.101671_bib3","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.berh.2021.101671_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2021.101671_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2741\/s22","article-title":"Transforming growth factor-beta in systemic sclerosis (scleroderma)","volume":"1","author":"Varga","year":"2009","journal-title":"Front Biosci (Schol Ed)."},{"issue":"12","key":"10.1016\/j.berh.2021.101671_bib7","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2021.101671_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2021.101671_bib10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2397198319841842","article-title":"Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease","volume":"4","author":"Wollin","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"issue":"26","key":"10.1016\/j.berh.2021.101671_bib11","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1136\/annrheumdis-2020-217331","article-title":"Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial","volume":"79","author":"Seibold","year":"2020","journal-title":"Ann Rheum Dis"},{"year":"2019","author":"US Food and Drug Administration","series-title":"FDA approves first treatment for patients with rare type of lung disease","key":"10.1016\/j.berh.2021.101671_bib13"},{"year":"2020","series-title":"Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease","key":"10.1016\/j.berh.2021.101671_bib14"},{"issue":"18","key":"10.1016\/j.berh.2021.101671_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2021.101671_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib17","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2021.101671_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"Sabnani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2021.101671_bib19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2021.101671_bib20","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","article-title":"Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial","volume":"167","author":"Prey","year":"2012","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2021.101671_bib21","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar4606","article-title":"Low-Dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6 Suppl 86","key":"10.1016\/j.berh.2021.101671_bib22","first-page":"S189","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial","volume":"32","author":"Gordon","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187580","article-title":"Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Martyanov","year":"2017","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.berh.2021.101671_bib24","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"Faseb J"},{"issue":"1","key":"10.1016\/j.berh.2021.101671_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","article-title":"Nilotinib (TasignaTM) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial","volume":"17","author":"Gordon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.berh.2021.101671_bib26","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2021.101671_bib27","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI116015","article-title":"Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4","volume":"90","author":"Postlethwaite","year":"1992","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.berh.2021.101671_bib28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8982","key":"10.1016\/j.berh.2021.101671_bib29","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(95)91744-6","article-title":"Role of thrombin in pulmonary fibrosis","volume":"346","author":"Hernandez-Rodriguez","year":"1995","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2021.101671_bib30","first-page":"S367","article-title":"Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?","volume":"153","author":"Chambers","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib31","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/art.24935","article-title":"Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts","volume":"60","author":"Bogatkevich","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2021.101671_bib32","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","article-title":"Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease","volume":"63","author":"Bogatkevich","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2021.101671_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/acr2.11049","article-title":"Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease","volume":"1","author":"Silver","year":"2019","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2021.101671_bib34","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking noncanonical TGF\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2021.101671_bib35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2021.101671_bib36","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/1756-185X.13386","article-title":"5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-\u03b21 induced non-canonical signaling pathways including STAT3: implications for fibrotic diseases like scleroderma","volume":"21","author":"Chaturvedi","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2021.101671_bib37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/annrheumdis-2016-eular.5587","article-title":"The serotonin receptor 2 inhibitor terguride has beneficial effects on skin fibrosis: results from a phase 2 proof of concept study","volume":"75","author":"Distler","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2021.101671_bib38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.berh.2021.101671_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/thoraxjnl-2011-200717","article-title":"Proteasomal inhibition after injury prevents fibrosis by modulating TGF-\u03b21 signalling","volume":"67","author":"Mutlu","year":"2012","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.berh.2021.101671_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1208\/s12248-009-9084-5","article-title":"Cannabinoids, endocannabinoids, and related analogs in inflammation","volume":"11","author":"Burstein","year":"2009","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.berh.2021.101671_bib41","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Garcia-Gonzalez","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2021.101671_bib42","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013778","article-title":"PPAR\u03b3 downregulation by TGF\u00df in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.berh.2021.101671_bib44","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2021.101671_bib45","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2021.101671_bib46","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10067-018-4298-5","article-title":"Dysregulation of the Wnt signaling pathway in South African patients with diffuse systemic sclerosis","volume":"38","author":"Frost","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2021.101671_bib47","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","article-title":"Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82","volume":"137","author":"Lafyatis","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2021.101671_bib48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.berh.2021.101671_bib49","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","article-title":"Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-\u03b2 signaling in scleroderma fibroblasts","volume":"175","author":"Asano","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.berh.2021.101671_bib50","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1073\/pnas.85.4.1105","article-title":"Transforming growth factor \u03b2 increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability","volume":"85","author":"Penttinen","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.berh.2021.101671_bib51","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human antitransforming growth factor \u03b21 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2021.101671_bib52","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.berh.2021.101671_bib53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2021.101671_bib54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"120","key":"10.1016\/j.berh.2021.101671_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1183\/09059180.00001111","article-title":"Antifibrotic activities of pirfenidone in animal models","volume":"20","author":"Schaefer","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"1\u20133","key":"10.1016\/j.berh.2021.101671_bib56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(02)01758-2","article-title":"A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-\u03b1 at the translational level","volume":"446","author":"Nakazato","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.berh.2021.101671_bib57","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2021.101671_bib58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694221000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:22:25Z","timestamp":1761499345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694221000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1521694221000139"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2021.101671","relation":{},"ISSN":["1521-6942"],"issn-type":[{"type":"print","value":"1521-6942"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotics in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2021.101671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101671"}}